Administration of a 1-phenylalkanecarboxylic acid before, after, or a concurrently with a therapeutically effective amount of one or more of the following: (1) β-amyloid peptides level reducers, (2) pathogenic level tau reducers, (3) microtubule stabilizers, (4) agents capable or removing atherosclerotic plaques, (5) agents that lower circulating levels of β-amyloid and tau, (6) modulators of autophagy, (7) neurotransmitter levels regulators, (8) GABA(A) α5 Receptor Antagonists, and (9) additional agents that help maintain and/or restore cognitive function and functional deficits of AD, and/or slow down decline in cognitive functions and functional deficits in AD, is useful for prevention or therapeutical treatment of proteinopathies and/or neurodegenerative diseases.
